1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCon Edison's EnergyShare program assists low-income residential customers in New York experiencing financial difficulties and facing potential termination of service, providing financial relief to help them afford their energy bills.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Low-income residential customers of Con Edison in New York City and Westchester County who are experiencing financial difficulties and facing potential termination of service. Confirm the full requirements in the official notice before applying.
The current listing shows up to $300 annually (for residential customers). Verify award ceilings, matching requirements, and allowable costs in the official notice.
EnergyShare (New York) is funded by Con Edison (administered by HeartShare Human Services of NY). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
On August 26, 2026, NSF named the STC class of 2026: TEMPEST at Michigan State, GENIE at Northwestern, and a human-robot co-adaptation center at UT Austin. $90 million total, $6 million a year each. The 2023 class was four centers and $120 million. The award size is intact; the shelf space shrank 25 percent — and that is the number that should reshape how you plan a center proposal.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Complement-ARIE program funds seven technology centers to develop human-based models that complement animal research. What it means for drug developers, academic researchers, and the regulatory pipeline.
Read article